Kodiak Sciences Announces Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
PALO ALTO, Calif., March 28, 2023 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the fourth quarter ended December 31, 2022. “We are running a comprehensive development program for tarcocimab tedromer with topline data from four … Continued